PrimeVigilance
PrimeVigilance is recorded as a service provider in 164 clinical trials. Explore its recorded services, study phases and therapeutic areas, with trial-level operational learnings where available.
Clinical trial experience
Showing 20 of 164 trials · Latest update first
A Phase III, single arm, multicentre study to evaluate the efficacy and safety of ropeginterferon alfa-2b in essential thrombocythaemia patients who are intolerant or refractory to or not eligible for other cytoreductive treatments
Sponsor Aop Orphan Pharmaceuticals GmbH
- Start (EU)
- Latest update
- Estimated end
- Not reported
Study of Elironrasib (RMC-6291), With or Without Daraxonrasib (RMC-6236), in Combination With Other Anti-Cancer Agents, in Patients With RAS G12C-Mutated Non-Small Cell Lung Cancer – Subprotocol A
Sponsor Revolution Medicines Inc.
- Start (EU)
- Latest update
- Estimated end
A Long-Term Extension Trial Investigating the Safety and Efficacy of GTX-102 in Patients with Angelman Syndrome
Sponsor Ultragenyx Pharmaceutical Inc.
- Start (EU)
- Latest update
- Estimated end
A Phase 2 Study to Evaluate the Safety, Tolerability, and Clinical Activity of BLU-808, a Wild Type KIT Inhibitor, in Chronic Inducible Urticaria and Chronic Spontaneous Urticaria
Sponsor Blueprint Medicines Corp.
- Start (EU)
- Latest update
- Estimated end
A Phase 3, Randomized, Double-Masked, Active-Controlled Trial of a Single Intravitreal Injection of 4D-150 in Adults with Macular Neovascularization Secondary to Age-Related Macular Degeneration (4FRONT-2)
Sponsor 4d Molecular Therapeutics Inc.
- Start (EU)
- Latest update
- Estimated end
A Long-Term Extension Study to Assess the Efficacy, Safety, and Tolerability of IMVT-1402 in Adult Patients With Graves' Disease
Sponsor Immunovant Sciences GmbH
- Start (EU)
- Latest update
- Estimated end
RASolute 303: A Phase 3 Global, Multicenter, Open-label, Randomized, 3-Arm Study of Daraxonrasib Monotherapy or Daraxonrasib Plus Gemcitabine and Nab-paclitaxel versus Gemcitabine and Nab-paclitaxel as a First-Line Treatment for Patients with Metastatic Pancreatic Adenocarcinoma
Sponsor Revolution Medicines Inc.
- Start (EU)
- Latest update
- Estimated end
Long-Term Low-Intervention SafEty and Clinical Outcomes Clinical Study of LivmArli® in Patients with Alagille Syndrome or Progressive Familial Intrahepatic Cholestasis in the European Union (LEAP-EU)
Sponsor Mirum Pharmaceuticals Inc.
- Start (EU)
- Latest update
- Estimated end
- Not reported
A RANDOMIZED, PHASE 3, OPEN-LABEL STUDY OF NEOADJUVANT DAROVASERTIB IN SUBJECTS WITH PRIMARY NON-METASTATIC UVEAL MELANOMA (OptimUM-10)
Sponsor Ideaya Biosciences Inc.
- Start (EU)
- Latest update
- Estimated end
Multicentre, open-label, phase 1/2 study of LB-208, selective antagonist of the serotonin 5-hydroxytryptamine receptor 1B (HTR1B), in adults with relapse or refractory (r/r) acute myeloid leukaemia (AML) and r/r higher-risk (HR) myelodysplastic syndrome (MDS)
Sponsor Aop Orphan Pharmaceuticals GmbH
- Start (EU)
- Latest update
- Estimated end
- Not reported
An Extension Study of JR-141 to Evaluate the Long-term Safety and Efficacy in Mucopolysaccharidosis Type II (Hunter Syndrome) Subjects
Sponsor Jcr Pharmaceuticals Co. Ltd.
- Start (EU)
- Latest update
- Estimated end
A PHASE 2, OPEN-LABEL, RANDOMIZED, NON-COMPARATIVE CLINICAL TRIAL OF ADP-A2M4CD8 MONOTHERAPY AND IN COMBINATION WITH NIVOLUMAB IN SUBJECTS WITH RECURRENT OVARIAN CANCERS (SURPASS-3 STUDY/ GOG-3084)
Sponsor USWM Ct LLC
- Start (EU)
- Latest update
- Estimated end
A Double-Blind, Placebo-Controlled, Multicenter, Randomized Phase 3 Trial Evaluating the Efficacy and Safety of Felzartamab in Kidney Transplant Recipients with Late Antibody-Mediated Rejection (AMR) (TRANSCEND / 299AR301)
Sponsor Biogen Idec Research Limited
- Start (EU)
- Latest update
- Estimated end
A Phase 3, Randomized, Double-blind, Placebo-controlled Study of Felzartamab in Adults with IgA Nephropathy (299IG301 / PREVAIL)
Sponsor Biogen Idec Research Limited
- Start (EU)
- Latest update
- Estimated end
A Phase 3, Randomized, DoubleBlind, Placebo-controlled, Multicenter, Parallel-group Study to Evaluate the Efficacy and Safety of Once Daily Treprostinil Palmitil Inhalation Powder in Participants with Pulmonary Arterial Hypertension (PALM-PAH)
Sponsor Insmed Inc.
- Start (EU)
- Not reported
- Latest update
- Estimated end
A Phase 3 Multicenter, Double-Masked, Randomized, Placebo-Controlled Study to Investigate the Safety, Tolerability, and Efficacy of Gildeuretinol Acetate (ALK-001) on the Progression of Stargardt Disease (STGD) - NORTHSTAR
Sponsor Alkeus Pharmaceuticals Inc.
- Start (EU)
- Not reported
- Latest update
- Estimated end
A Phase 1/2, Multicenter, Open-label Study of IMGN632 Monotherapy Administered Intravenously in Patients with CD123-positive Acute Myeloid Leukemia and Other CD123-positive Hematologic Malignancies
Sponsor AbbVie Deutschland GmbH & Co. KG
- Start (EU)
- Latest update
- Estimated end
A Phase 2 Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, in Adults and Children with PIK3CA Related Overgrowth Spectrum and Malformations Driven by PIK3CA Mutation
Sponsor Relay Therapeutics Inc.
- Start (EU)
- Latest update
- Estimated end
A Phase 2b, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess the Efficacy, Safety, and Tolerability of IMVT-1402 in Adult Participants with Primary Sjogren’s Disease with Moderate to Severe Systemic Disease Activity
Sponsor Immunovant Sciences GmbH
- Start (EU)
- Latest update
- Estimated end
A Phase 1b/2 Open-Label, Multicenter Study of Zoldonrasib (RMC-9805) with or without Daraxonrasib (RMC-6236), in Combination with Other Anticancer Agents, in Patients with RAS G12D-Mutated Non-Small Cell Lung Cancer (NSCLC) – Subprotocol C
Sponsor Revolution Medicines Inc.
- Start (EU)
- Latest update
- Estimated end
Questions about this trial experience
What services are recorded for PrimeVigilance?
The 2026-10-09 snapshot links PrimeVigilance to 164 distinct CTIS trials. Recorded services include Safety reporting & pharmacovigilance, Clinical monitoring, hosting the global safety database for the IMP, Hosting the global safety database for the IMP, among 19 recorded service labels. These are study-specific roles, not a complete or independently verified capability catalogue.
Which therapeutic areas and study phases are recorded for PrimeVigilance?
The most frequently recorded therapeutic areas are Genetic and Congenital Disorders, Immunology, Solid Tumor Oncology, Neurology. Recorded phases include Phase 2, Phase 3, Phase 1. Use the filters to inspect the supporting studies; missing tags are not evidence of absent experience.
In which countries are trials linked to PrimeVigilance conducted?
The linked trials record locations in 26 countries, including Spain, Germany, Italy, France, Poland. These are trial locations, not confirmed office locations or countries where PrimeVigilance delivered services.
What can this page tell me about PrimeVigilance's trial experience?
Browse 164 distinct trials with recorded roles, sponsor names, available study dates and links to CTIS source records. 1 trials have operational findings that can inform further due diligence. Trial counts and findings do not measure the provider’s performance or establish responsibility for study outcomes.
About this data & company names
One current approved profile per CTIS trial. Services reflect recorded roles, not a complete capability catalogue or a performance ranking. Missing tags mean the information was not recorded. Country tags describe trial locations, not the provider’s service territory.
Start is the reported EU start date; latest update is the CTIS publication date; estimated end is the reported global estimate, which may be in the past. Missing dates are shown as “Not reported”. Operational learnings describe the trial as a whole and do not establish the provider’s responsibility.
Clear service synonyms are grouped; otherwise the source label is retained. Service tags show the recorded roles for each trial. This page groups 5 recorded name variants under PrimeVigilance. Legacy brands remain separate unless explicitly matched in the name registry.
View recorded company names
- PrimeVigilance GmbH
- PrimeVigilance s.r.o.
- Primevigilance Limited
- Primevigilance USA Inc.
- Primevigilance Zagreb d.o.o.